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OBJECTIVES We hypothesized that pacemaker (PM) implantation in patients with myotonic dystrophy
(MD) with a prolonged HV interval, even asymptomatic, may protect them against sudden
death related to atrioventricular (AV) block. We sought to prospectively document the true
incidence of AV block episodes in this high-risk population and accurately trace, in the long
term, by the PM, the occurrence of arrhythmias that may remain undetected during
conventional follow-up.
BACKGROUND Myotonic dystrophy is associated with a high risk of sudden death, commonly attributed to
AV block or ventricular arrhythmias, but cardiac pacing is only recommended as a secondary
prevention.
METHODS Patients with MD with an HV interval 70 ms, even in the absence of related symptoms,
prospectively received a cardiac PM, including an algorithm capable of diagnosing episodes
of bradycardia and tachyarrhythmias.
RESULTS The population consisted of 49 patients (45.5  8.9 years old) followed for 53.5  27.2
months. Paroxysmal arrhythmias were recorded in 41 patients (83.7%), consisting of complete
AV block (n  21), sino-atrial block (n  4), or atrial (n  25) or ventricular (n  13)
tachyarrhythmias. No patient died of AV block during follow-up, but 10 deaths occurred, 4
of them sudden. An arrhythmic cause could be excluded by postmortem PM interrogation in
two cases of typical sudden death.
CONCLUSIONS Arrhythmias are common in patients with MD with infrahisian conduction abnormalities.
The prophylactic implantation of a pacing system when the HV interval is 70 ms seems
appropriate. The PM protects the patient against the clinical consequences of paroxysmal
profound bradycardia and facilitates the diagnosis and management of frequent paroxysmal
tachyarrhythmias. (J Am Coll Cardiol 2002;40:1645–52) © 2002 by the American College
of Cardiology Foundation
Myotonic dystrophy (MD) is a serious autosomal-dominant
hereditary disease with an estimated incidence of 1 in 8,000
births (1–3). Death is a major concern in MD, although its
reported incidence varies widely, and may be related to
muscular weakness or respiratory failure, or sometimes it
may be sudden (4–13). The most often proposed mecha-
nisms of sudden death in MD are atrioventricular (AV)
conduction disorders and ventricular tachyarrhythmias
(4,6,8,9,11,14–21). Practice guidelines recommend the im-
plantation of a cardiac pacemaker (PM) in patients with
MD in case of acquired third-degree AV block (class I
indication) or if there is the incidental finding, during
electrophysiologic (EP) study, of a markedly prolonged HV
interval (100 ms) in asymptomatic patients (class IIa
indication) (22).
In our study, we put forward the hypothesis that implan-
tation of a PM in patients with MD with an HV interval
70 ms, even asymptomatic, may protect them against the
risk of sudden death related to AV block. The aims of this
multicenter study were: 1) to prospectively justify the PM
indication by automatic recording of spontaneous AV block
episodes in patients with MD without previously docu-
mented bradycardia; and 2) to use the PM to accurately
record the occurrence of cardiac bradyarrhythmias and
tachyarrhythmias that may remain undetected during con-
ventional clinical follow-up.
METHODS
Patient recruitment and testing. The study was approved
by the Ethical Review Committee of the Cochin School of
Medicine. After having given their written, informed con-
sent to participate, the patients were enrolled into the study
in eight medical centers, between 1993 and 1996. The
Appendix lists the institutions and investigators participat-
ing in this study. Molecular genetic testing was performed
as previously described (23). The diagnosis of MD was
confirmed by the finding, on deoxyribonucleic acid extracted
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from peripheral blood samples, of an expansion of the
cytosine-thymine-guanine triplet over 50.
Electrophysiologic testing was performed, as previously
described (24), in the presence of symptomatic or asymp-
tomatic AV conduction abnormalities (first-degree or
higher AV block and/or widening of the QRS complex
100 ms), palpitations or documented arrhythmias, or near
syncope or syncope, or preoperatively in preparation for
major surgery under general anesthesia.
The main study inclusion criteria consisted of an HV
interval 70 ms, even in the absence of related symptoms.
Patients with documented bradycardia requiring cardiac
pacing could also be included, with the sole objective of
recording spontaneous tachyarrhythmias.
Before implantation of a diagnostic dual-chamber PM
(Chorus RM 7034, Ela medical, Le Plessis Robinson,
France), a 12-lead rest electrocardiogram (ECG), 24-h
ambulatory ECG, signal-averaged ECG, transthoracic
echocardiogram, and right and left ventricular radionuclide
angiograms were obtained.
Algorithm specifications. A specific diagnostic algorithm
was downloaded to the random-access memory of the PM,
allowing the diagnosis of bradycardias and tachycardias at
the ventricular level during the VDI mode (ventricular
pacing and sensing plus atrial sensing). Two types of
bradycardic events—“pauses” and “bradycardias”—were de-
fined (Fig. 1). The diagnosis of “tachycardia,” based on
ventricular rate analysis, was made when the following
criteria were present: 1) a beat-to-beat heart rate accelera-
tion 25% at the initiation of the tachycardia; 2) a heart
rate 154 beats/min; and 3) for more than five consecutive
cycles. With each event, the time and date were memorized,
along with marker chains, all retrievable by PM interroga-
tion. Each marker chain included atrial and ventricular
events preceding and following the diagnostic cycle, allow-
ing clarification of the nature of the event (Fig. 2).
Patient follow-up. Follow-up visits were scheduled every
six months, at which time the patients’ clinical status and
surface ECG were recorded, and a complete PM interro-
gation was performed, including retrieval of the diagnostic
algorithm data. Important clinical events were recorded by
interviewing the patient, the family, or the patient’s primary
physician. In case of death, if possible, the PM was
interrogated to determine whether the death was arrhyth-
mic.
Statistical analyses. Data are reported as the mean value
SD. The rates of AV block, sino-atrial (SA) block, and atrial
and ventricular tachyarrhythmias were analyzed for the
entire follow-up period by life-table analysis. Kaplan-Meier
survival curves were constructed; the patients who died or
were no longer being followed up were censored. The
prognostic values of factors measured at baseline, that could
be related to the occurrence of AV block, SA block, and
tachyarrhythmias, were tested by the log-rank test. Cox
proportional hazards models were used to study the effect of
several factors simultaneously and to adjust for the potential
confounding effect of age. All computations were performed
with the SAS package (SAS User’s Guide Statistics 1990,
version 6, SAS Institute Inc., Cary, North Carolina).
RESULTS
Study population. The study population consisted of 49
patients (24 men and 25 women; 45.5  8.9 years old).
Their main baseline clinical characteristics are summarized
in Table 1. Forty-five patients had no history of docu-
mented bradycardia before study entry. In this group, 11
complained of palpitations, 16 experienced syncope or
fainting episodes before EP testing, and 25 had no cardiac
symptoms and underwent EP testing because of conduction
disturbances on the surface ECG. Only two patients had a
normal ECG and underwent EP testing for investigation of
syncope in one case and for palpitations and near syncope in
the other.
Four patients had documented bradycardia before study
inclusion: asymptomatic infrahisian 2:1 AV block (n  1),
infrahisian complete AV block with syncope (n  1),
Abbreviations and Acronyms
AV  atrioventricular
ECG  electrocardiogram/electrocardiographic
EP  electrophysiologic
MD  myotonic dystrophy
PM  pacemaker
SA  sino-atrial
Figure 1. Diagnostic algorithm for bradycardic events. In addition to a
backup rate (basic), a watch rate (50 beats/min) and a pause rate (30
beats/min) are defined. The spontaneous ventricular rate (Vs) may fall
below the backup rate to the pause rate, at which point ventricular pacing
(Vp) is initiated. (A) A “pause” is confirmed after two consecutive
ventricular cycles paced at the pause rate of 30 beats/min, triggering the
memorization of a marker chain. (B) A marker chain of “bradycardia” is
stored after 100 consecutive ventricular cycles between the watch and pause
rates. Thereafter, rescue ventricular pacing begins, gradually rising to the
backup rate. Open circle  Vs; Closed circle  Vp. Vs  ventricular
sensed event; Vp  ventricular paced event.
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asymptomatic paroxysmal third-degree AV block on the
24-h ambulatory ECG (n  1), and complete absence of
atrial activity, without ventricular escape, following electri-
cal cardioversion of atrial flutter (n  1).
Long-term follow-up. Over a mean observation period of
53.5 27.2 months (median 57.5 months, maximum 101.4
months), 10 patients died and 4 patients left the study on
their physician’s recommendation (n  2), because of PM
memory failure (n  1), or because of study protocol
violation (n  1). The circumstances of the 10 deaths,
including 4 sudden deaths, were clarified in all but 2 cases
(Table 2). In two patients who died suddenly, PM interro-
gation performed shortly after death excluded an arrhythmic
death, because no arrhythmia was stored by the diagnostic
algorithm. Their heart rate trend only showed a moderate
acceleration of sinus rhythm a few minutes before death.
During 425 follow-up visits (range 1 to 18 follow-up
visits per patient), 21 patients (43%) reported symptoms
Figure 2. Marker chain of paroxysmal complete atrioventricular block. The intervals displayed correspond to RRs or PPs intervals. P  spontaneous
P-wave; R  spontaneous R-wave; V  paced ventricle.
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consisting of dyspnea (n  6), palpitations (n  9), fainting
(n  9), or syncope (n  1). In 18 patients, no rythmologic
explanation was found for symptoms sometimes atypical; in
3 patients, the symptoms coincided with an arrhythmia
memorized by the PM: palpitations related to atrial fibril-
lation (n  1) or bitachycardia (n  1) and dyspnea due to
2:1 AV block (n  1).
Marker chain analysis. In 41 (83.7%) of the 49 patients,
marker chains indicative of arrhythmias were retrieved from
the PM’s memory. A marker chain of “pause” was present in
23 (51.1%) of 45 patients without previously documented
bradycardia (Fig. 3) due to high-degree paroxysmal AV
block (n  21) and/or paroxysmal complete SA block (n 
4). The cumulative incidences of pauses at 6, 12, 24, and 48
months were 22.2%, 37.8%, 46.7%, and 48.9%, respectively.
Pauses were exclusively nocturnal in 35% of cases of AV
block and in all cases of SA block.
Algorithm criteria of “bradycardia” due to marked sinus
bradycardia were confirmed in 24 patients (53%), mostly
(75.1%) during the night.
In 28 patients (57.1%), “tachycardia” (Fig. 4) was re-
corded due to atrial arrhythmias with rapid AV conduction
in 25 patients (51%) and/or ventricular tachycardia in 13
patients (26.5%). The cumulative incidences of tachycardias
at 6, 12, 24 and 48 months were 22.4%, 32.7%, 40.8%, and
51%, respectively. Atrial and ventricular arrhythmias were
strictly diurnal in 54.5% and 72.7%, respectively, and strictly
nocturnal in only 13.6% and 18.2%, respectively.
Statistical analysis. No statistical association was found
between the occurrence of AV or SA block and several
variables, including age, gender, severity of muscle disease,
rest heart rate, conduction intervals (PR, QRS, and HV, or
H duration), corrected sinus node recovery time, SA con-
duction time, signal-averaged ECG, anti-arrhythmic treat-
ment, or history of syncope or near syncope.
After adjustment for age, the occurrence of atrial arrhyth-
mias was associated with the number of supraventricular
extrasystoles recorded on the 24-h ambulatory ECG, with a
relative risk of 4.2 (95% confidence interval 1.3 to 12.9)
beyond 1,000 extrasystoles per 24 h. Atrial arrhythmias were
not associated with age, gender, severity of muscular disease,
corrected sinus node recovery time, SA conduction time,
right atrial refractory period, induction of atrial arrhythmia
by programmed stimulation, left atrial diameter, vital ca-
pacity, or history of palpitations.
No direct or age-adjusted statistical association was found
between the incidence of ventricular arrhythmias and age,
gender, muscular weakness, anti-arrhythmic treatment, ven-
tricular extrasystoles on the 24-h ambulatory ECG, right
ventricular refractory period, induction of ventricular ar-
rhythmia by programmed stimulation, results of the signal-
averaged ECG, left or right ventricular ejection fraction, or
history of palpitations, syncope, or near syncope.
The occurrence of death was positively associated with
age (p  0.005, r  1.1) and the degree of muscular
weakness (p  0.01, r  1.76), and negatively correlated
with the pulmonary vital capacity (p  0.01, r  0.93) and
anti-arrhythmic drug treatment with amiodarone or beta-
blockers (p  0.03, r  0.18).
Surface ECG findings. Among the 45 patients without
documented bradycardia before study entry, surface ECG
recordings during follow-up visits revealed the development
of high-degree AV block in 5 patients at 25, 51, 56, 64, and
88 months of follow-up (Fig. 5). Of these five patients, two
patients had no history of syncope or fainting; two patients
had fainting episodes; and one patient reported syncope
before implantation of the PM. In three of five cases,
paroxysmal third-degree AV block was detected by the PM
Table 1. Baseline Characteristics of Patient Population
Mean  SD Range
Age (yrs) 45.5  8.9 19–67
CTG repeat sequences (n) 921  441 185–1,750
Vital capacity (ml) 2447  813 980–4,488
Radionuclide LVEF (%) 59  10.6 38–79
Radionuclide RVEF (%) 35.9  9.7 9–51
Left atrial diameter (mm) 33.2  6.2 20–48
PACs on 24-h ambulatory ECG (n) 426  994 0–4,413
PVCs on 24-h ambulatory ECG (n) 452  965 0–5,410
PR interval (ms) 223  36 160–320
QRS duration (ms) 127  30 60–200
SA conduction time (ms) 150  99 20–369
Corrected sinus node recovery time (ms) 427  266 50–1,200
AH interval (ms) 110  37 45–200
H duration (ms) 23  8 10–45
HV interval (ms) 79  11 70–125
Atrial refractory period (ms) 218  35 160–320
Ventricular refractory period (ms) 249  30 190–320
# of Patients
Arrhythmic history
Atrial fibrillation/flutter 3/3
Monomorphic PVCs ( 200 per 24 h) 2
Torsades de pointes 1
Sustained monomorphic VT 1
Surface ECG
First-degree AV block 27
2:1 AV block 1
Third-degree AV/SA block 1/1
LAFB 13
Incomplete/complete RBBB 1/5
Incomplete/complete LBBB 5/8
LAFB and RBBB 2
Nonspecific IVCD 5
Programmed stimulation Nonsustained Sustained
Atrial (n  39)
Atrial fibrillation 1 6
Atrial flutter 0 2
Atrial tachycardia 1 1
Ventricular (n  43)
Monomorphic VT 0 2
Polymorphic VT 6 0
Ventricular fibrillation 1 1
AV  atrioventricular; CTG  cytosine-thymine-guanine; ECG  electrocardio-
gram; IVCD  intraventricular conduction delay; LAFB  left anterior fascicular
block; LBBB and RBBB  left and right bundle branch block, respectively; LVEF
and RVEF  left ventricular and right ventricular ejection fraction, respectively;
PAC  premature atrial complex; PVC  premature ventricular complex; SA 
sino-atrial; VT  ventricular tachycardia.
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algorithm during the first month after implantation. Two
patients had no previous marker chain recording of AV
block because, against the study protocol, their device had
been reprogrammed 11 to 20 months earlier to the DDD
mode, which is a mode that does not allow the identification
of bradycardic events.
One patient developed permanent SA block on the
surface ECG at 81 months, as predicted by the PM that
stored a marker chain of complete SA block 16 months after
implantation.
Seven patients had atrial fibrillation on routine ECG
recordings, becoming chronic in 5 cases after 7 to 77
months of follow-up. In all cases, an episode of paroxysmal
atrial fibrillation with a rapid ventricular rate had been
previously diagnosed by the PM.
One patient complained of dizziness 71 months after
implantation, related to a sustained bitachycardia (mono-
morphic ventricular tachycardia and atrial flutter) present
both on the surface ECG and in the PM’s memory.
DISCUSSION
To our knowledge, this study is the first to use an implant-
able diagnostic device providing an accurate diagnosis of
spontaneous bradycardias and tachyarrhythmias, even when
the patient is asymptomatic, associated with antibradycardia
support. This diagnostic tool was applied to patients with
MD (Steinert’s disease) in the largest series published thus
far of paced patients with this disorder, which is associated
with a high risk of arrhythmias and sudden death.
High incidence of AV block. A high incidence of arrhyth-
mic events was observed. Indeed, 41 (83.7%) of the 49
patients had an arrhythmic event recorded by the PM’s
diagnostic algorithm during follow-up. High-degree parox-
ysmal AV block was recorded in 46.7% of patients who had
no known bradycardia on study entry. All but one of the
bradycardic events were asymptomatic, as they were brief or
associated with pauses limited by backup pacing. The PM
protected our 49 patients from the consequences of pro-
Table 2. Fatal Outcomes in 10 Patients
Pt.
No.
Post-Implant Follow-Up
(months)
Sudden
Death
Pacemaker
Interrogated Cause of Death
1 10 Yes Yes Undetermined; arrhythmia excluded by pacemaker interrogation
2 49 Yes Yes Undetermined; arrhythmia excluded by pacemaker interrogation
3 53 Yes No Asystole during acute decompensation of chronic respiratory
failure and severe ischemic cardiomyopathy
4 23 Yes No Unknown
5 57 No No Acute decompensation of chronic respiratory failure
6 58 No No Chronic respiratory failure
7 82 No No Acute decompensation of chronic respiratory failure
8 83 No No Embolic cerebral/vascular accident
9 59 No No Massive pulmonary embolism
10 56 No No Unknown
Autopsy was not performed in any of the patients.
Figure 3. Kaplan-Meier analysis of the incidence of bradyarrhythmias observed during follow-up, diagnosed as “pauses” by the pacemaker algorithm, and
corresponding to either complete sino-atrial block (SAB) or high-degree atrioventricular block (AVB).
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found bradycardia. Reprogramming the PM to the DDD
mode (sequential atrioventricular sensing and pacing) after
documentation of paroxysmal AV block prevented subse-
quent symptomatic bradyarrhythmias. The strictly nocturnal
occurrence of some of the episodes of AV block may suggest a
functional precipitant—for example, sleep apnea, a disorder
often associated with MD (25,26). However, the diurnal
occurrence of most episodes of AV block, as well as prolonga-
tion of the HV interval at study entry, points to the importance
of infrahisian disease. In addition, the observation of fixed 2:1
or third-degree AV block on the surface ECG in five patients,
months after the recording of paroxysmal third-degree AV
block by the PM, supports the hypothesis of an organic
etiology. The data stored by the PM during follow-up confirm
the validity of PM implantation. Considering these results,
prophylactic permanent pacing should be considered in pa-
tients with MD when the HV interval is 70 ms, even
without related symptoms, and not when the HV interval
exceeds 100 ms, as previously recommended (22).
Severe sinus node dysfunction with paroxysmal third-
degree SA block, later observed on the surface ECG in one
case, was documented in only 9% of patients, exclusively at
night. This observation militates in favor of a functional
precipitant, perhaps sleep apnea, although one of the four
patients had an abnormal sinus node recovery time on study
entry.
Atrial and ventricular arrhythmias. The high number of
paroxysmal atrial arrhythmias recorded confirms their fre-
quent occurrence in patients with MD (24). Although no
statistically significant relationship was established in this
study, the high incidence of atrial arrhythmias recorded
during follow-up was consistent with the patients’ history of
atrial arrhythmias and the results of programmed atrial
stimulation before PM implantation. A density of atrial
extrasystoles1,000 per 24 h on the 24-h ambulatory ECG
was the only variable associated with the subsequent occur-
rence of atrial arrhythmias. It is noteworthy that the actual
incidence of atrial arrhythmias was probably underestimated,
because their detection was limited to episodes associated with
rapid AV node conduction, as the diagnostic algorithm ac-
counts only for the ventricular rate. The importance of these
atrial arrhythmias is illustrated in the development of chronic
atrial fibrillation in 5 patients between 0 and 28 months after
the first recorded arrhythmic episode.
Of the several variables examined, the number of atrial
extrasystoles on the 24-h ambulatory ECG was the sole
predictor of atrial arrhythmias. In view of the small size of
our study population, we were able to identify relative risks
of 2 and 3 with powers of 20% and 75%, respectively, by
statistical analysis, except for ventricular arrhythmias, which
occurred so infrequently as to preclude a power calculation.
Consequently, predictive factors of an only moderate rela-
tive risk may have been missed.
Spontaneous ventricular tachycardia was recorded in 13
patients. Although highly symptomatic ventricular arrhyth-
mias have been described in MD (4,6,8,9,11,15–19), no
poorly tolerated episode was observed among our patients.
Only one patient complained of palpitations during bitachy-
cardia. The predominantly diurnal incidence (72.7%) of
these arrhythmias suggests their facilitation by sympathetic
activity. Although a negative correlation has been found
between age and arrhythmia induction by programmed
ventricular stimulation (24), no correlation was found in this
study between the results of EP testing and subsequent
recordings of ventricular arrhythmias.
All tachyarrhythmias were identified by the PM algo-
rithm before being diagnosed by conventional follow-up
methods. Furthermore, when anti-arrhythmic drug treat-
Figure 4. Kaplan-Meier analysis of the incidence of atrial and ventricular tachyarrhythmias observed during the follow-up period.
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Figure 5. In March 1994, the presence of asymptomatic conduction disturbances on the surface electrocardiogram (ECG) prompted electrophysiologic testing in this 51-year-old woman with myotonic
dystrophy. After the finding of a prolonged HV interval (70 ms), a pacemaker was implanted. During the first month after implantation, marker chains of paroxysmal high-degree atrioventricular (AV) block
were recorded. In September 2000, 2:1 AV block was observed on the surface ECG. In March 2002, pacemaker dependency was demonstrated during temporary pacemaker inhibition, with underlying complete
AV block, as shown on this ECG tracing (paper speed 25 mm/s).
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ment was indicated, the PM allowed us to monitor the
efficacy of the therapy.
Causes of death during long-term follow-up. No death
related to AV block occurred. Four of the 10 deaths, one of
which was sudden, were due to acute respiratory insuffi-
ciency. This 40% rate is comparable to the 42% death rate
from respiratory failure in the Canadian population de-
scribed by Mathieu et al. (12) in a cohort of unselected
patients with a common ancestor. It is consistent with the
finding, in our study, of a statistical link between the risk of
death and a lower vital capacity or more severe muscular
weakness. As in the Canadian study, we observed a higher
incidence of sudden death than that expected in a young
population. However, this incidence was considerably
higher in our population, reaching 8.2% at 53.5 months, as
compared with 2.2% at 120 months in the Canadian study.
Furthermore, mortality may have been limited by perma-
nent pacing, preventing death from AV block, as well as by
the early treatment of asymptomatic paroxysmal tachyar-
rhythmias, reducing the risk of a spontaneous adverse evolu-
tion. Anti-arrhythmic drug treatment with amiodarone or
beta-blockers demonstrated a protective effect in our study.
No arrhythmic cause was identified in three of our four
patients who died suddenly. This demonstrates that typical
sudden death can be nonarrhythmic in MD.
Conclusions. As expected, we found a high incidence of
paroxysmal complete AV block in patients with MD with
infrahisian conduction abnormalities, even without history of
related symptoms. The prophylactic implantation of a pacing
system when the HV interval reaches 70 ms should then be
recommended to protect patients against the clinical conse-
quences of paroxysmal profound bradycardia. A PM including
detailed diagnostic functions also facilitates the diagnosis and
management of frequent paroxysmal tachyarrhythmias that
may remain undetected during conventional clinical follow-up.
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